News

Note: This story was updated Sept. 26, 2022, to correct the fact that Abecma is approved for patients in Europe and Japan who have undergone at least three prior therapies, not four as originally stated.  The CAR T-cell therapy Abecma (idecabtagene vicleucel) significantly extended survival without signs of disease worsening…

Telo Genomics has teamed up with the Mayo Clinic to develop tests to help clinicians identify multiple myeloma (MM) patients at high risk of experiencing a relapse after treatment. The new research into such drug resistance assessment measures follows the ongoing development of a previous test to detect…

STAR-LLD, an investigational continuous delivery of low doses of lenalidomide into the blood — being developed as a new treatment option for multiple myeloma — was well-tolerated in healthy volunteers in a Phase 1 clinical trial, with no dose-related toxicity or adverse events, data show. Moreover, the treatment…

A combination of the investigational therapy teclistamab and the approved medication Darzalex (daratumumab) reduced the cancer burden for most people with relapsed or refractory multiple myeloma (RRMM) in a clinical trial. The patients in the study had received from two to 17 prior lines of therapy, with a median…

The European Commission has granted full approval to a triple combination therapy of Nexpovio (selinexor) — sold in the U.S. as Xpovio —  to treat adults with multiple myeloma who have received at least one previous line of therapy. The approval covers Nexpovio in combination with Velcade (bortezomib)…

A branch of the European Medicines Agency (EMA) has recommended that Janssen’s investigational therapy Tecvayli (teclistamab) be granted conditional marketing authorization for adults with relapsed and refractory multiple myeloma (RRMM). The recommendation, from the EMA’s Committee for Medicinal Products for Human Use (CHMP), specifically supports Tecvayli for patients…

Oncopeptides received a positive opinion from an arm of the European Medicines Agency (EMA) that is expected to take the company one step closer toward European Union approval to market Pepaxti (melphalan flufenamide, also called melflufen) in combination with dexamethasone for hard-to-treat multiple myeloma. With the Committee for Medicinal…

Note: This story was updated July 13, 2022, to correct the name of Rare-X’s CEO Charlene Son Rigby. Nonprofits, scientists, governmental organizations, and the rare disease drug development industry have long cited 7,000 as the average number of rare diseases in the world.

Talquetamab, a first-in-class antibody treatment being developed by Janssen Research & Development, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for hard-to-treat multiple myeloma. The designation was awarded based on the positive safety and efficacy findings of a Phase 1/2 clinical trial involving adults…

The China National Medical Products Administration (NMPA) has agreed to review an application for Equecabtagene autoleucel — the country’s first chimeric antigen receptor (CAR) T-cell therapy — for relapsed or refractory multiple myeloma. The CAR T-cell therapy, the first to be developed domestically in China, was awarded breakthrough…